SCHEMBL23498481

SCHEMBL23498481

CCc1csc2c(N(Cc3ccco3)C(=O)OC(C)(C)C)nc(Cl)nc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAPT P10636 8/20 0.38
RAB9A P51151 1/20 0.38
POLB P06746 1/20 0.36
ALDH1A1 P00352 6/20 0.36
LMNA P02545 2/20 0.36
RIPK1 Q13546 1/20 0.35
TP53 P04637 5/20 0.35
KDM4E B2RXH2 5/20 0.35
HPGD P15428 4/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29997987 0.90 TSHR (0.38) TSHRMEN1KMT2AL3MBTL1CYP1A2
SCHEMBL29998125 0.90 KDM4E (0.38) TSHRMEN1KMT2AL3MBTL1CYP1A2
SCHEMBL23498448 0.90 TSHR (0.38) TSHRMEN1KMT2AL3MBTL1CYP1A2
SCHEMBL25066371 0.90 KDM4E (0.38) TSHRMEN1KMT2AL3MBTL1CYP1A2
SCHEMBL23498859 0.88 TSHR (0.45) TSHRMEN1KMT2AL3MBTL1CYP1A2
SCHEMBL23498793 0.84 MAPT (0.47) TSHRMEN1KMT2AL3MBTL1MAPT
SCHEMBL29997949 0.82 TP53 (0.39) TSHRMEN1KMT2AL3MBTL1CYP1A2
SCHEMBL25066131 0.82 TP53 (0.39) TSHRMEN1KMT2AL3MBTL1CYP1A2
SCHEMBL23499108 0.82 ALDH1A1 (0.37) TSHRMEN1KMT2AL3MBTL1CYP1A2
SCHEMBL25066334 0.80 ALDH1A1 (0.33) TSHRMEN1KMT2AL3MBTL1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230057568-A1 COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA PTC THERAPEUTICS, INC. (US) 2023-02-23 US disclosed
EP-4072677-A1 COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA PTC Therapeutics, Inc. (US) 2022-10-19 EP disclosed
WO-2021118929-A1 COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA PTC THERAPEUTICS, INC. (US) 2021-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230057568-A1 COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA SNRPB2, SYNCRIP, HNRNPUL2 TSHR 2908/4885MEN1 1139/4885KMT2A 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.